Bonus BioGroup Ltd. (BBIXF) Research

Bonus BioGroup Ltd., an Israeli biotechnology company founded in Haifa in 1981 (and formerly known as Oceana Advanced Industries Ltd.), is dedicated to developing innovative solutions for regenerating bone tissue. The firm specializes in creating autologous bone grafts, meaning they are derived from a patient's own cells, to address various skeletal conditions such as bone trauma and arthritis. Their flagship products include BonoFill, an injectable bone graft designed for general bone repair applications, like treating jaw bone cysts. They also offer a pre-designed BonoFill graft specifically engineered to reconstruct significant and segmented bone deficiencies. In its research and development pipeline, Bonus BioGroup is actively advancing new bone grafts for maxillofacial and orthopedic uses, exploring novel nanomaterial technologies for tissue regeneration, and developing large vascularized bone grafts.

Market snapshot

Symbol
BBIXF
Price
$0.13
Day change
0.00%
Market cap
$383.1M
P/E ratio
-12.37x
52-week range
0.0001-0.15
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Cell Source, Inc. (CLCS)
  • Cordlife Group Limited (CLIFF)
  • Celyad Oncology S.A. (CLYYF)
  • Evolva Holding S.A. (ELVAF)
  • Finch Therapeutics Group, Inc. (FNCH)
  • ImpediMed Limited (IPDQF)
  • Institute of Biomedical Research Corp. (MRES)
  • Resverlogix Corp. (RVXCF)

Open Bonus BioGroup Ltd. (BBIXF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.